newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track